U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H16N4O3S
Molecular Weight 368.41
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VE-821

SMILES

CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(N)C(=N2)C(=O)NC3=CC=CC=C3

InChI

InChIKey=DUIHHZKTCSNTGM-UHFFFAOYSA-N
InChI=1S/C18H16N4O3S/c1-26(24,25)14-9-7-12(8-10-14)15-11-20-17(19)16(22-15)18(23)21-13-5-3-2-4-6-13/h2-11H,1H3,(H2,19,20)(H,21,23)

HIDE SMILES / InChI

Molecular Formula C18H16N4O3S
Molecular Weight 368.41
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22825331

VE-821 is a potent ATP-competitive inhibitor of ATR (Ki of 13nM). VE-821 shows excellent selectivity for ATR with minimal cross-reactivity against the related PIKKs ATM, DNA-dependent protein kinase (DNA-PK), mammalian target of rapamycin and phosphoinositol 3-kinase-γ (Ki s of 16 uM, 2.2 uM, >1 uM and 3.9 uM, respectively) and against a large panel of unrelated protein kinases. VE-821 has being shown to increase sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
13.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
2011 Apr 13
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
2011 Apr 14
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
2012 Sep
Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60).
2013 Nov
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
VE-821 (2 and 10 uM) reduced the number of irradiated HL-60 cells in the G2 phase to the level of non-irradiated cells and increased the number of irradiated cells in S phase, compared to irradiated cells not treated with inhibitors.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:14:25 GMT 2023
Edited
by admin
on Sat Dec 16 16:14:25 GMT 2023
Record UNII
BF884TQ935
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VE-821
Code English
3-AMINO-6-(4-(METHYLSULFONYL)PHENYL)-N-PHENYL-2-PYRAZINECARBOXAMIDE
Systematic Name English
2-PYRAZINECARBOXAMIDE, 3-AMINO-6-(4-(METHYLSULFONYL)PHENYL)-N-PHENYL-
Systematic Name English
3-AMINO-6-(4-(METHYLSULFONYL)PHENYL)-N-PHENYLPYRAZINE-2-CARBOXAMIDE
Common Name English
3-AZANYL-6-(4-METHYLSULFONYLPHENYL)-N-PHENYL-PYRAZINE-2-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
CAS
1232410-49-9
Created by admin on Sat Dec 16 16:14:25 GMT 2023 , Edited by admin on Sat Dec 16 16:14:25 GMT 2023
PRIMARY
EPA CompTox
DTXSID60679574
Created by admin on Sat Dec 16 16:14:25 GMT 2023 , Edited by admin on Sat Dec 16 16:14:25 GMT 2023
PRIMARY
FDA UNII
BF884TQ935
Created by admin on Sat Dec 16 16:14:25 GMT 2023 , Edited by admin on Sat Dec 16 16:14:25 GMT 2023
PRIMARY
PUBCHEM
51000408
Created by admin on Sat Dec 16 16:14:25 GMT 2023 , Edited by admin on Sat Dec 16 16:14:25 GMT 2023
PRIMARY